Article Details

Truist sees upside in Sangamo stock with milestone payments and Fabry disease advancements

Retrieved on: 2024-12-13 17:54:00

Tags for this article:

Click the tags to see associated articles and topics

Truist sees upside in Sangamo stock with milestone payments and Fabry disease advancements. View article details on hiswai:

Excerpt

On Friday, Truist Securities shifted its stance on Sangamo BioSciences (NASDAQ:SGMO), raising the stock's rating from Hold to Buy and setting a ...

Article found on: www.investing.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up